Scarica l'app Stockscreener
17.47
1.36%
-0.24
Pre-mercato:
17.40
-0.07
-0.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
MSN Money - MSN
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Wall Street Zen Downgrades Dyne Therapeutics (NASDAQ:DYN) to Strong Sell - MarketBeat
Understanding the Setup: (DYN) and Scalable Risk - Stock Traders Daily
DYN Stock Chart | DYNE THERAPEUTICS INC (NASDAQ:DYN) - ChartMill
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells 227,337 Shares of Stock - MarketBeat
Dyne therapeutics director Jason Rhodes sells $4.18m in stock By Investing.com - Investing.com Australia
Dyne therapeutics director Jason Rhodes sells $4.18m in stock - Investing.com
Dyne Therapeutics(DYN.US) Director Sells US$4.18 Million in Common Stock - Moomoo
Dyne Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Rhodes Jason P - Moomoo
Atlas Venture funds tied to Dyne (DYN) director sell 227,337 shares - Stock Titan
Could Dyne Therapeutics (DYN) Turn Its FORCE Platform Into a Broader Neurology Franchise? - simplywall.st
Dyne Therapeutics earnings up next: DMD launch path in focus By Investing.com - Investing.com India
Dyne Therapeutics earnings up next: DMD launch path in focus - Investing.com
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: Pharma - openPR.com
Dyne Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Dyne Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Lubner David Charles - Moomoo
Director at Dyne Therapeutics (DYN) makes bona fide gift of 53,625 shares - Stock Titan
Dyne Therapeutics Insider Sold Shares Worth $7,101,120, According to a Recent SEC Filing - marketscreener.com
Dyne therapeutics director Jason Rhodes sells $7.1m in stock By Investing.com - Investing.com South Africa
Dyne Therapeutics (NASDAQ:DYN) Director Sells $3,148,897.95 in Stock - MarketBeat
Dyne Therapeutics(DYN.US) Director Sells US$7.1 Million in Common Stock - Moomoo
Dyne therapeutics director Jason Rhodes sells $7.1m in stock - Investing.com
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting - The Manila Times
Dyne Therapeutics Announces Upcoming Presentation - GlobeNewswire
Dyne Therapeutics (DYN) Stifel 2026 Virtual CNS Forum Summary - Quartr
Dyne Therapeutics (DYN) Proxy filing Summary - Quartr
Dyne Therapeutics (DYN) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Dyne Therapeutics director Kersten sells $219k in company stock - Investing.com
Dyne Therapeutics director Kersten sells $219k in company stock By Investing.com - Investing.com India
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
[ARS] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Director-affiliated fund trims Dyne Therapeutics (DYN) stake in 10b5-1 sales - Stock Titan
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):